Gemfibrozil


Concise Prescribing Info
Indications/Uses
Hyperlipidaemias.
Dosage/Direction for Use
Adult : PO 1.2 g/day in 2 divided doses.
Dosage Details
Oral
Hyperlipidaemias
Adult: 1.2 g daily in 2 divided doses. Alternatively, 900 mg as a single dose in the evening.
Renal Impairment
Mild to moderate (GFR 30-80 mL/min/1.73m2): Initially, 900 mg daily. Severe: Contraindicated.
Hepatic Impairment
Contraindicated.
Administration
Should be taken on an empty stomach. Take 30 min before meals.
Contraindications
History of photosensitivity or phototoxic reaction w/ fibrates. History of or pre-existing gall bladder or biliary tract disease (e.g. gallstones). Severe Hepatic (including primary biliary cirrhosis) and severe renal impairment. Lactation. Concomitant use w/ repaglinide, dasabuvir, or statins.
Special Precautions
Pregnancy. Mild to moderate renal impairment.
Adverse Reactions
Significant: Myopathy, myositis, rhabdomyolysis, elevated hepatic transaminases and CPK, decreased Hb, haematocrit, WBC; increased risk of cholelithiasis, malignancy. Rarely, bone marrow hypoplasia, anaemia, eosinophilia, leucopenia, thrombocytopenia.
Nervous: Dizziness, drowsiness, headache, fatigue, paraesthesia, depression, peripheral neuritis/neuropathy, vertigo, headache.
CV: AF.
GI: Dry mouth, taste disturbance, appendicitis, diarrhoea, constipation, nausea, vomiting, abdominal pain, flatulence.
Resp: Laryngeal oedema.
Hepatic: Cholecystitis, cholestatic jaundice.
Genitourinary: Impotence, reduced libido.
Musculoskeletal: Myasthenia, muscle pain, myalgia, synovitis.
Ophthalmologic: Blurred vision.
Dermatologic: Exfoliative dermatitis, circumscribed exanthema, pruritus, urticaria, angioedema, dermatomyositis, eczema, rash. Rarely, photosensitivity.
Others: Hypokalaemia.
Patient Counseling Information
Avoid exposure to sunlight.
MonitoringParameters
Monitor lipid, blood sugar, blood count, and LFT.
Overdosage
Symptoms: Abdominal pain, cramps, abnormal LFT, diarrhoea, increased creatine phosphokinase (CPK), joint and muscle pain, nausea and vomiting. Management: Symptomatic and supportive treatment. In acute overdosage, perform gastric lavage immediately.
Drug Interactions
Increases the plasma concentration of rosiglitazone, pioglitazone, bexarotene. May potentiate the effect of coumarin type vit K antagonist anticoagulants (e.g. warfarin). Reduced bioavailability when given w/ resin-granule drugs (e.g. colestipol).
Potentially Fatal: Risk of severe hypoglycaemia w/ repaglinide. Increases dasabuvir exposure which may result in increased risk of QT prolongation. Increased risk of muscle related adverse effects (e.g. myopathy, rhabdomyolysis) w/ statins (e.g. simvastatin).
Action
Description: Gemfibrozil is a fibric acid derivative which decreases serum triglycerides and VLDL, and increases HDL cholesterol. The exact mechanism of its action has not been fully established but it has been shown to inhibit lipolysis of fat in adipose tissue and decrease hepatic fatty acid reuptake. It also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule of VLDL.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the GI tract. Bioavailability: Approx 100%. Time to peak plasma concentration: W/in 1-2 hr.
Distribution: Plasma protein binding: Approx 98%.
Metabolism: Metabolised in the liver via oxidation into hydroxymethyl and carboxyl metabolites; undergoes enterohepatic recirculation.
Excretion: Mainly via urine (approx 70%, mainly as glucuronide conjugates and metabolites); faeces (6%). Elimination half-life: Approx 1.5 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Protect from light and moisture.
ATC Classification
C10AB04 - gemfibrozil ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Disclaimer: This information is independently developed by MIMS based on Gemfibrozil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Ipolipid
  • Pharmaniaga Gemfibrozil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in